3D Medicines says Phase III data for Envafolimab plus GEMOX in advanced biliary tract cancer to be presented at 2026 ASCO meeting

• 3D Medicines flagged Phase III results for envafolimab with GEMOX in first-line advanced biliary tract cancer for presentation at the 2026 ASCO annual meeting.
• The data have not yet been presented; the poster is scheduled for May 30, 2026, 9:00 a.m.–12:00 p.m. CDT.
• The trial showed favorable survival outcomes for the combination versus GEMOX alone, supporting a potential expansion of envafolimab’s use in China.
• Envafolimab, a subcutaneous PD-L1 inhibitor co-developed with Alphamab Oncology, has generated cumulative sales of over RMB 2 billion in China.
• The group also reported three additional studies accepted for ASCO 2026, adding to its oncology pipeline visibility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3D Medicines Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260527-12172044), on May 27, 2026, and is solely responsible for the information contained therein.